Testing peginterferon for RSV lung infection in young children
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a medication called peginterferon to treat RSV bronchiolitis (a lung infection causing wheezing and breathing trouble) in children ages 6 months to 2 years. It aims to see if the drug helps them recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 months and 2 years old.
- Your child must test positive for RSV through a nose swab.
- Your child must have symptoms like fast breathing, wheezing, or signs of lung congestion.
- Symptoms must have started within the last 3 days.
- Your child cannot have used other antiviral drugs or immune medicines in the last 3 weeks.
- Your child cannot have a severe chronic illness (like heart, lung, liver, or kidney problems) or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows babies under 12 months old who are hospitalized with bronchiolitis to understand their treatment and outcomes. It includes tracking RSV testing and a new immunization called nirsevimab, which may help protect against severe illness.
This study looks at how the bacteria in the gut and the immune system respond in infants hospitalized with severe RSV infection. It may help doctors understand why some babies get sicker and could lead to better treatments.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
This trial tests if an inhaled interferon solution can help children under 2 years old with a moderate to severe RSV lung infection. It aims to reduce symptoms like cough and trouble breathing.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
Hear when a new Bronchiolitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.